Product Description: DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype[1][2].
Applications: Cancer-programmed cell death
Formula: C22H20N2O6
References: [1]Chatterjee A, et al. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novelcamptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60./[2]Sriram Rajagopal, et al. Preclinical evaluation of the anticancer activity of DRF-1042, a novel camptothecin analog targeting Topoisomerase-I. Published April 2004.
CAS Number: 200619-13-2
Molecular Weight: 408.40
Compound Purity: 98.05
Research Area: Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: ADC Cytotoxin;Topoisomerase
English
Deutsch
